Komori
Solasia Pharma K.K. (4597) · PolicyRestated

Application of IFRS 16 “Leases”

First written in FY2019-Q1. 5 of 6 entries say "Restated". Latest entry: FY2023-Q2.

6entries
5years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2019-Q1 – FY2023-Q22019: 220192020: 020202021: 120212022: 120222023: 22023
Same theme, other companies
IFRS 16 (Leases) ImplementationA theme 147 companies write about · 2 as a headwind · 1 as a tailwind

The whole theme swung hardest in 2025: 6 of 19 companies on the "Worse" side.

72 other companies' latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 147 companies compared. The sentences above are computed from all 147.
Full recordFilings, disclosures and news, newest first
  1. FY2023-Q2RestatedAnnual report

    「The significant accounting policies applied to the Group’s condensed quarterly consolidated financial statements are the same as those applied to the consolidated financial statements for the previous consolidated fiscal year.」

    重要な会計方針に前連結会計年度から変更がない状態を継続している。
  2. FY2022RestatedAnnual report

    「当社グループの連結財務諸表は、国際会計基準(以下「IFRS」という。)に基づいて作成しています。」

    IFRSに基づく連結財務諸表の作成方針を継続している。
  3. FY2022-Q1RestatedAnnual report

    「当社グループの要約四半期連結財務諸表において適用する重要な会計方針は、前連結会計年度の連結財務諸表において適用した会計方針と同一です。」

    重要な会計方針は前連結会計年度から変更されていない。
  4. FY2021-Q3RestatedAnnual report

    「当社グループの要約四半期連結財務諸表において適用する重要な会計方針は、前連結会計年度の連結財務諸表において適用した会計方針と同一です。」

    前連結会計年度から重要な会計方針に変更はない。
  5. FY2019-Q3RestatedAnnual report

    「The Group has applied IFRS 16, “Leases,” from the first quarter of the consolidated fiscal year.」

    IFRS第16号「リース」の適用を継続している。
  6. FY2019-Q1First statedAnnual report

    「The Group has applied IFRS 16, Leases, published in January 2016, from the first quarter of the current fiscal year.」

    The Group applied IFRS 16 from 1 January 2019 and recognized right-of-use assets of ¥92 million and lease liabilities of ¥93 million at the end of the first quarter.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Solasia Pharma K.K. yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Application of IFRS 16 “Leases” | Solasia Pharma K.K. (4597) | Komori